Publications

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-Up in Patients with Highly Active Disease: Post Hoc Analysis of Care-Ms I and Ii Patients in the Topaz Extension Study

AuthID
P-00S-HB9

Author(s)

Ziemssen, T

Bass, AD

Berkovich, R

Comi, G

Eichau, S

Hobart, J

Hunter, SF

LaGanke, C

Limmroth, V

Pelletier, D

Pozzilli, C

Schippling, S

Sousa, L

Traboulsee, A

Uitdehaag, BMJ

Van Wijmeersch, B

Choudhry, Z

Daizadeh, N

Singer, BA

Group Author(s)

CARE-MS I Investigators; CARE-MS II Investigators; CAMMS03409 Investigators; TOPAZ Investigators

Document Type

Article

Year published

2020

Published

in CNS DRUGS, ISSN: 1172-7047

Volume: 34, Issue: 9, Pages: 973-988 (16)

Indexing

Wos^®

Scopus^®

Pubmed^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1007/s40263-020-00749-x

Pubmed: 32710396

SCOPUS: 2-s2.0-85088573106

Wos: WOS:000552160400001

Source Identifiers

ISSN: 1172-7047

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-Up in Patients with Highly Active Disease: Post Hoc Analysis of Care-Ms I and Ii Patients in the Topaz Extension Study

Useful Links

Get Help

Federated Authentication (Click on the image)

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-Up in Patients with Highly Active Disease: Post Hoc Analysis of Care-Ms I and Ii Patients in the Topaz Extension Study

Useful Links

Get Help